A large retrospective cohort pharmacoepidemiologic study found that despite approval by the U.S. Food and Drug Administration (FDA) for seven new gram-negative antibiotics between 2014 and 2019, clinicians in U.S. hospitals still treated more than 40% of patients battling highly resistant pathogens exclusively with older, generic agents. Furthermore, nearly 80% of the time these older agents are already known to be highly toxic or sub-optimally effective.
This article was originally published on MedicalXpress.com
